Healsun Biopharm Closes ￥80 Million Series A Financing

(VCBeat) Apr. 12, 2021 -- Hangzhou Healsun Biopharm Co. Ltd. ("Healsun Biopharm"), a one-stop service platform for antibodies and recombinant protein drugs from gene editing to clinical sample production, announced it has raised 80 million RMB in a Series A funding round, co-led by Kington Capital and Hai Bang Capital, with participation from Yinxinggu Capita and Sinowisdom. Chana Capital acted as the sole financial advisor. The funds are earmarked for the construction of Healsun Biopharm's four new 500L production lines to improve the company's capacity in clinical sample production and CDMO.

Previously, Healsun Biopharm completed strategic financing of 50 million yuan in 2018 from industrial investors.

Healsun Biopharm was established in November 2015 and is a technical service company specializing in the development of antibodies and recombinant protein drugs. The company has nearly 10,000 square meters of R&D and office space in Hangzhou headquarters and Shanghai branch.

Healsun Biopharm provides new drug R&D services and has a technical platform such as stable cell plant development, cell fermentation technology development, purification technology development, analytical method development, formulation development, and trial production. 

Since its establishment, Healsun Biopharm has provided biomedical technology R&D services for a number of pharmaceutical companies at home and abroad, and at the same time reached strategic cooperation with several listed companies. The company's first co-developed antibody drug also entered the clinical declaration stage in the first half of 2018.

Founded in 2016, Kington Capital is a private equity fund management platform wholly owned by Suzhou Private Capital Investment Holding Co., Ltd. Kington Capital has nearly 20 years of experience in the investment and financing of technology enterprises, and has invested in strategic emerging industries such as biomedicine and new-generation information technology.

Hai Bang Capital is an investment company focusing on venture investment and private equity. Hai Bang Capital is focused on technology innovation, connecting capital and technology. In addition to providing capital, Hai Bang Capital provides its invested companies with personalized value-added services, stimulating both the national economy and social benefits.